Given the above described correlations of residual enzymatic ASS1 activity with the metabolic disease course and cognitive outcome, we next investigated, whether this observation also holds true for other clinical features like movement disorder, tone change, hepatocellular injury, and kidney dysfunction. The gene discussed is ASS1; the disease is metabolic disease.